Active	Status	Sponsor type	Region	Phase	Filter
7 Active 0 Inactive 7 All	Not yet recruiting Recruiting Enrolling by invitation Active, not recruiting Available No longer recruiting	Industry lead sponsor Industry collaborator Coop Other	US Canada Japan Europe RoW	N/A 1 2 3 4	Highlight changes:- Show only changed items Enrollment:

Advanced Filters

3 Trials

Active Trials   Industry lead sponsorIndustry collaborator

 

Export

Trial + Data / Events	Status	Ph	N	Region	Interventions	Sponsor	Conditions	Primary compl	Study compl
Bruna, Riccardo
KCP-330-009, NCT02227251 / 2014-001977-15: Selinexor (KPT-330) in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020 Dec 2020 - Dec 2020: Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020 Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020 Dec 2020 - Dec 2020: Subset analysis data from SADAL trial for r/r DLBCL at ASH 2020 Data from SADAL trial in DLBCL Jun 2020 - Jun 2020: Data from SADAL trial in DLBCL From trial for DLBCL Jun 2020 - Jun 2020: From trial for DLBCL From SADAL trial in DLBCL at EHA 2020 May 2020 - May 2020: From SADAL trial in DLBCL at EHA 2020 Data from SADAL trial in DLBCL at ICML 2019 [screenshot] Jun 2019 - Jun 2019: Data from SADAL trial in DLBCL at ICML 2019 [screenshot] Data from SADAL trial at ASH 2018 [screenshot] Dec 2018 - Dec 2018: Data from SADAL trial at ASH 2018 [screenshot] SADAL trial data for DLBCL at EHA 2017 Jun 2017 - Jun 2017: SADAL trial data for DLBCL at EHA 2017 Top-line data from SADAL trial in DLBCL at AACR 2017 Apr 2017 - Apr 2017: Top-line data from SADAL trial in DLBCL at AACR 2017 More	Recruiting	2	244	Europe, Canada, US, RoW	Selinexor, KPT-330	Karyopharm Therapeutics Inc	Diffuse Large B-cell Lymphoma	04/27	11/27
FIL_POLARDHAP, NCT05966233: R-DHAP vs POLA-R-DHAP Followed by Autologous Transplant as First Salvage Treatment in Patient With Relapsed or Refractory Diffuse Large B Cell Lymphoma	Withdrawn	2	150	Europe	R-DHAP, Pola-R-DHAP	Fondazione Italiana Linfomi - ETS, Roche Pharma AG	Diffuse Large B Cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent	01/29	01/29
FIL_MAB, NCT06008691: A Prospective, Observational Cohort Study on the Clinical Impact of Novel Monoclonal Antibodies in B-cell Non-Hodgkin Lymphoma in Italian Clinical Practice	Recruiting	N/A	1500	Europe	"novel" MAB (alone or in combination)	Fondazione Italiana Linfomi - ETS, Roche Pharma AG	Non-Hodgkin Lymphoma, B-cell	10/38	10/38